XML 25 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Preferred Stock
Class C Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Other Comprehensive Loss
Total
Balance, Beginning at Dec. 31, 2020 $ 2,844 $ 40 $ 566,451 $ (192,013) $ 5,376 $ 382,698
Balance, Beginning (in shares) at Dec. 31, 2020 250,000 39,837,058        
Net loss       (275,528)   (275,528)
Other comprehensive income, net of taxes         (6,619) (6,619)
Stock-based compensation expense     15,334     15,334
Issuance of common stock for board of director compensation     11     11
Issuance of common stock for board of director compensation (in shares)   229        
Cost of Series C preferred stock conversion     (1,800)     (1,800)
Issuance of common stock in public offering, net of costs of $17.7 million   $ 4 269,821     269,825
Issuance of common stock in public offering, net of costs of $17.7 million (in shares)   4,356,059        
Issuance of common stock in direct placement, net   $ 3 248,908     248,911
Issuance of common stock in direct placement, net (in shares)   3,072,038        
Conversion of Series C preferred shares to common stock $ (765) $ 1 764      
Conversion of Series C preferred shares to common stock (in shares) (50,000) 1,312,860        
Paid-in-kind preferred stock dividend, including beneficial conversion feature $ 8,196   (8,196)      
Proceeds from exercise of stock options   $ 2 8,994     8,996
Proceeds from exercise of stock options (in shares)   1,037,910        
Balance, Ending at Dec. 31, 2021 $ 10,275 $ 50 1,100,287 (467,541) (1,243) 641,828
Balance, Ending (in shares) at Dec. 31, 2021 200,000 49,616,154        
Net loss       (37,333)   (37,333)
Other comprehensive income, net of taxes         (33,306) (33,306)
Stock-based compensation expense     20,082     20,082
Paid-in-kind preferred stock dividend $ 8,000   (8,000)      
Issuance of common stock for Cell&Co acquisition (in shares)   15,152        
Issuance of common stock for Cell&Co acquisition     479     $ 479
Repurchase of common stock (in shares)   (1,604,994)       (1,604,994)
Repurchase of common stock   $ (2)   (37,958)   $ (37,960)
Vesting of restricted stock units (in shares)   101,070        
Proceeds from exercise of stock options     2,048     2,048
Proceeds from exercise of stock options (in shares)   206,898        
Balance, Ending at Dec. 31, 2022 $ 18,275 $ 48 1,114,896 (542,832) (34,549) 555,838
Balance, Ending (in shares) at Dec. 31, 2022 200,000 48,334,280        
Net loss       (99,587)   (99,587)
Other comprehensive income, net of taxes         8,484 8,484
Stock-based compensation expense     22,808     $ 22,808
Paid-in-kind preferred stock dividend $ 8,000   (8,000)      
Repurchase of common stock (in shares)           0
Vesting of restricted stock units (in shares)   228,932        
Proceeds from exercise of stock options   $ 1 1,479     $ 1,480
Proceeds from exercise of stock options (in shares)   407,814        
Balance, Ending at Dec. 31, 2023 $ 26,275 $ 49 $ 1,131,183 $ (642,419) $ (26,065) $ 489,023
Balance, Ending (in shares) at Dec. 31, 2023 200,000 48,971,026